Loading...
http://jcps.bjmu.edu.cn

Table of Content

    29 June 2017, Volume 26 Issue 6
    Original articles
    The impact of Rho GTPases on the cell uptake of single-walled carbon nanohorns
    Hongzhe Fu, Jiafang Song, Ge Song, Siyang Song, Zhipu Fan, Anpu Yang, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang
    2017, 26(6):  395-403.  DOI: 10.5246/jcps.2017.06.043
    Asbtract ( 302 )   HTML ([an error occurred while processing this directive])   PDF (1822KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Rho GTPases play an important role on the regulation of cytoskeleton, which can affect the cell morphogenesis, cell migration, endocytosis and vesicle transport by controlling the growth and maintenance of microfilaments and microtubules. It has been known that regulation of cell cytoskeleton is inseparable from the cell uptake of nano-medicine or nano-drug delivery systems. However, only few studies have focused on the impacts of Rho GTPases on cell uptake of nano-medicine or nano-drug delivery systems. This study selected single-walled carbon nanohorns (SWCNHs), which have emerged as promising drug delivery systems, to explore the impacts of Rho GTPases on cell uptake of nano-drug delivery systems. SWCNHs were oxidized with concentrated nitric acid and prepared into nano dispersion by ultrasonic dispersion. Confocal laser scanning microscope (CLSM) and transmission electron microscopy (TEM) were used to observe the cell uptake and intracellular distribution of nanoparticles after incubated A549 cells with the dispersion mentioned above. Mechanism of cell uptake was assessed using various inhibitors. The results showed that the cell uptake of oxSWCNHs was significantly reduced when RhoA was inhibited. The oxSWCNHs were internalized through clathrin-mediated endocytosis and mainly positioned in lysosomes of A549 cells.

    A highly sensitive LC-MS/MS method for the determination of 21-hydroxy deflazacort in nude mice plasma and its application to a pharmacokinetic study
    Qingyu Yao, Jian Li, Ye Yao, Rong Chen, Wenjun Chen, Hong Su, Liang Yang, Junsheng Xue, Wei Lu, Tianyan Zhou
    2017, 26(6):  404-412.  DOI: 10.5246/jcps.2017.06.044
    Asbtract ( 429 )   HTML ([an error occurred while processing this directive])   PDF (1432KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    In the current study, we established and validated a simple and sensitive liquid chromatography-tandem mass spectrometricmethod for the determination of 21-hydroxy deflazacort in nude mice plasma, and such a method was applied to a pharmacokinetic study. Using betamethasone as the internal standard, the plasma samples were pre-treated by precipitation with acetonitrile and then analyzed on a reversed-phase C18 column (50 mm×2 mm, 5 μm) with a mobile phase consisting of acetonitrile and 4.0 mM ammonium formate (pH was adjusted to 3.5 with formic acid (40:60, v/v)). The analyte was detected by a triple quadrupole tandem mass spectrometer using electrospray, and multiple reaction monitoring was employed to select 21-hydroxy deflazacort at m/z 400.2/124.0 and betamethasone at m/z 393.3/147.0 in the positive ion mode. The calibration curves were linear (r>0.99) over the range of 0.5–400 ng/mL. The intra- and inter-day precisions and accuracies were 4.5%–10.1% and –1.7%~10.7% respectively. This method was successfully applied to a preclinical pharmacokinetic study of deflazacort on female nude mice administered with a single oral dose of 4 mg/kg deflazacort, and its pharmacokinetics was characterized by a two-compartment model with first-order absorption. 

    Lappaconitine solid dispersion monolithic osmotic tablet and lappaconitine push-pull osmotic pump: preparation and comparison of their release performance in vitro
    Xianchuang Wu, Jiaojiao Wang, Haijun Hao, Xiaoyong Song, Yongzhou Zhang, Yuxin Liu, Hongqin Zhang
    2017, 26(6):  413-422.  DOI: 10.5246/jcps.2017.06.045
    Asbtract ( 276 )   HTML ([an error occurred while processing this directive])   PDF (1492KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Lappaconitine is a water-insoluble drug, which was used as model drug in this study. Currently, two osmotically controlleddelivery systems that are widely used for water-insoluble drug are monolithic osmotic tablet (MOT) and push–pull osmotic pump (PPOP). In the present study, lappaconitine solid dispersion monolithic osmotic tablet (lappaconitine-SD-MOT) and lappaconitine-PPOP were developed. The prepared lappaconitine-PPOP was able to delivery drug at the rate of approximate zero-order (r = 0.9931), and the cumulative release was above 95.0%. The lappaconitine-SD-MOT showed a comparatively poor linearity when the data were plotted according to the zero-order equation (r = 0.9798), and the cumulative release was 84.69%. Lappaconitine-PPOP exhibited better controlled drug release (higher regression value) compared with lappaconitine-SD-MOT. The similarity index (f2) between lappaconitine-PPOP and lappaconitine-SD-MOT was 49.1 (<50). A clear difference of drug release characteristics between the lappaconitine-SD-MOT and lappaconitine-PPOP was revealed. It indicated that the drug release performance of lappaconitine-PPOPcould gain favorable zero-order kinetics and higher cumulative release compared with lappaconitine-SD-MOT. Therefore, these results suggested that PPOP was still a very effective device for the delivery of poorly water-soluble drug with zero-order pattern.

    Genome-wide identification of long noncoding RNAs in myocyte differentiation
    Qin Yang, Dong Li, Chao Feng, Yi Fan, Hua Li, Quan Du
    2017, 26(6):  423-431.  DOI: 10.5246/jcps.2017.06.046
    Asbtract ( 225 )   HTML ([an error occurred while processing this directive])   PDF (1731KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Taking advantage of high-throughput sequencing technology, a large number of long noncoding RNAs (lncRNAs) have been recently characterized. Emerging evidence suggests that they play critical roles in diverse biological processes, including the differentiation of skeletal muscle cells. As previous studies have focused mainly on the polyadenylated lncRNAs, the involvement of polyA-minus lncRNAs in myocyte differentiation remains largely unexplored. To this aspect, their expression and regulation were examined in the present study. During the course of myocyte differentiation of C2C12 cells, polyA-minus RNAs were isolated and analyzed by RNA-seq. In addition to identifying 904 novel polyA-minus lncRNAs, their temporal expression was further characterized in this process. For many lncRNAs, differentiation-specific profiles were revealed. Based on their unique expression profiles, these lncRNAs were grouped into nine regulation categories. Taken together, our study greatly contributed to the identification of a dynamic regulation of polyA-minus lncRNAs, and clarified their potential roles in myocyte differentiation.

    Vanadium compounds induce stronger growth suppression in PTEN-deficient prostate cancer cells by ROS-mediated mechanism
    Yihua Hong, Tongtong Liu, Yanjun Liu, Jingxuan Wu, Xiaogai Yang
    2017, 26(6):  432-439.  DOI: 10.5246/jcps.2017.06.047
    Asbtract ( 337 )   HTML ([an error occurred while processing this directive])   PDF (1744KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    In the present study, we investigated the antiproliferative effect and the underlying mechanism of three antidiabetic vanadium compounds, metavanadate, VO(acac)2 and VO(ma)2, in human prostate cancer cells (PC-3 and DU-145). The results showed that vanadium compounds caused cell cycle arrest at G2/M phase evidenced by the elevation of phosphorylated Cdc2 at tyr-15. Moreover, the results revealed that vanadium compounds induced reactive oxygen species (ROS) elevation in the two cell lines. The decreased level of Cdc25C could be rescued by the antioxidant, N-acetylcysteine, indicating that vanadium compounds-induced G2/M arrest was mediated by ROS. Additionally, the three vanadium compounds exerted more potent growth inhibitory effect on PC-3 cells which are PTEN-deficient and with higher level of basal ROS. It suggested that PTEN protein might serve as a biomarker for the selectivity of antitumor therapy using ROS-generating agents. Since the studied vanadium compounds have been shown the antidiabetic activities in the previous studies, there may be additional benefits in the potential application of vanadium compounds to suppress the growth of prostate cancer cells. 

    Phenanthrenes, anthraquinones, and phenolic constituents from Sinomenium acutum
    Haining Lv, Mingbo Zhao, Yong Jiang, Pengfei Tu
    2017, 26(6):  440-446.  DOI: 10.5246/jcps.2017.06.048
    Asbtract ( 330 )   HTML ([an error occurred while processing this directive])   PDF (1152KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    A phytochemical investigation on the stems and rhizomes of Sinomenium acutum led to the isolation of 19 compounds, including three phenanthrenes, six anthraquinones, and ten phenolic derivatives. The structures of the isolated compounds were elucidated by analysis of the MS and NMR spectroscopic data and comparison with the literature. Compounds 1 and 2 are two new natural products, and their 1H and 13C NMR spectral data were fully assigned for the first time, with the help of 2D NMR. All of the isolates were obtained from genus Sinomenium for the first time and the phenanthrene and anthraquinone are the structure type first reported from this genus plants. 

    Drug administration and clinical pharmacy column
    Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
    Fangbing Lv, Kewei Yu, Wenwen Gao, Shuwen Yu
    2017, 26(6):  447-454.  DOI: 10.5246/jcps.2017.06.049
    Asbtract ( 399 )   HTML ([an error occurred while processing this directive])   PDF (1381KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Bevacizumab plus erlotinib prolonged patients’ progression-free survive (PFS) versus bevacizumab alone for the maintenance treatment of none-small cell lung cancer (NSCLC) in phase III clinical trial ATLAS (ClinicalTrials. gov identifier NCT00257608), which repealed a benefit outcome and acceptable side-effects, but whether its cost performance would be accepted by patients is blurry. The aim of our research is to figure out which strategy is the best option in clinic and would spread broadly. Markov Model was used to calculate incremental cost-utility radios (ICURs) and 10-year quality-adjusted life years (QALY) of both strategies. The clinical data were collected from phase III clinical trial ATLAS (ClinicalTrials. gov identifier NCT00257608).The cost data were obtained from Chinese health care system. In the research, one-way sensitivity analysis, probabilistic sensitivity analysis (PSA) and Monte-Carlo analysis were performed to test the stability of the results.The better strategy was bevacizumab alone strategy, and the cumulative costs of both strategies were $178 648.47 and $46 445.28, respectively, and the QALY was 12.506 and 10.643, respectively. The ICUR of combined application was $70 962.53/QALY, which was much higher than 3 times of mean gross domestic product (GDP) in China, suggesting that this strategy was no economical at all. In one-way analysis, the change of willingness-to-pay could not influence the consequence. In addition, in Monte-Carlo analysis, the probability distribution of cost, effectiveness and ICUR was in normal distribution.Taken together, bevacizumab alone strategy was the better strategy in terms of cost-effectiveness.

    An overview of expedited approaches in China’s drug review and approval regulation
    Tian Tian
    2017, 26(6):  455-459.  DOI: 10.5246/jcps.2017.06.050
    Asbtract ( 298 )   HTML ([an error occurred while processing this directive])   PDF (1119KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Nowadays, CFDA has released a series of reform documents in drug registration review system, which may optimize the new drug evaluation model to accelerate the development of drugs. In this review, we summarized the qualifications and features of expedited approaches in drug review and approval in China, and compared these approaches with FDA. In conclusion, the expedited programs of drug approval in China have been gradually established and translated into policy benefits for drug makers and patients.

    Short communication
    Antiplatelet aggregation activity of some ferrocenylphenylimine compounds
    Monisola I. Ikhile, Foluso O. Osunsanmi, Andy R. Opoku, J. Catherine Ngila
    2017, 26(6):  460-464.  DOI: 10.5246/jcps.2017.06.051
    Asbtract ( 234 )   HTML ([an error occurred while processing this directive])   PDF (1389KB) ([an error occurred while processing this directive])  
    References | Related Articles | Metrics

    Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (310), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine (3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine (4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine (5), N-(ferrocenylformidene)-3-ferrocenylimine (6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine (7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine (8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine (9), N-(ferrocenylformidene)-4-ferrocenylimine (10) on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds (310) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline (compound 1) and 4-ferrocenylaniline (compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists. 

    Other
    Information from US FDA——Impact of Severe Weather Conditions on Biological Products
    http://www.fda.gov
    2017, 26(6):  465-466. 
    Asbtract ( 135 )   HTML ( 0)   PDF (816KB) ( 34 )  
    Related Articles | Metrics

     

    CBER is providing interested persons with information concerning the storage and use of temperature-sensitive biological products that have been involved in a temporary electrical power failure or flood conditions. While people should not be put at risk by using a product that may be unsafe due to the conditions under which it was stored, shortages should not be created by discarding product simply because of power failures that may not adversely affect the product. Vials of biologicalproducts in contact with flood waters should be discarded given the possibility of contamination and the likelihood of significant exposure to temperatures outside of those recommended for cold chain storage.
    Most biological products require specific storage conditions, as indicated in the product labeling, to maintain their safety, purity, and potency. These products include bacterial and viral vaccines, allergenic extracts, plasma derivatives, and other products requiring refrigeration or frozen storage, as well as products that can be stored at controlled room temperature (i.e., not exceptionally cold or hot). When there is an electrical power failure, whether due to accident, equipment failure, or disruption in the electrical power grid, the temperature control systems for product storage may not function. For example, on August 14, 2003, the northeast region of the country experienced a power outage lasting from one to several days, and some health professionals were uncertain what to do with products that they had in storage. Power failures are not only a concern regarding storage in a facility, as failure of the refrigeration or freezer unit on a carrier (e.g., truck) while the products are in transit may also occur. The information below may assist interested persons in determining what to do with their biological products in the event of a power failure.